Tetrene Labs
Tetrene provides precision drug lead discovery services through its Crucible platform, which combines AI-driven modeling with classical mechanical simulations to generate optimized therapeutic candidates for any disease target. The disease-agnostic platform helps pharmaceutical companies accelerate drug development by reducing reliance on costly wet-lab experiments through computational verification.
- Drug Discovery & Therapeutics
- Artificial Intelligence
- Biotechnology
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Traditional drug lead discovery relies heavily on expensive and time-consuming wet-lab experiments, slowing the identification of viable therapeutic candidates. Pharmaceutical companies face significant costs and delays when screening and optimizing compounds for new disease targets, hampering the speed at which breakthrough medicines can reach patients.
Solution
Tetrene offers precision drug lead discovery services powered by its Crucible platform, a disease-agnostic computational algorithm that translates disease targets into optimized drug leads. Crucible blends AI-driven modeling with classical mechanical simulation techniques to rapidly generate and refine candidate compounds. The platform supports candidate generation, computational verification, ADMET property filtering, and custom AI fine-tuning to tailor results toward specific disease targets. By employing state-of-the-art computational verification at Tetrene Labs, the company minimizes the need for expensive wet-lab testing, enabling pharmaceutical partners to move promising compounds into development faster and more efficiently.
Target Audience
Primary customers are pharmaceutical companies and drug discovery organizations seeking computational lead identification services to accelerate their therapeutic development pipelines.
Features
- Crucible platform combining AI-driven modeling with classical mechanical simulations for drug lead optimization
- Disease-agnostic algorithm capable of understanding and translating any disease target into optimized drug leads
- Candidate generation with user-defined lead compound quantities and binding affinity acceptance criteria
- Computational verification services to confirm candidate viability and prioritize the most valuable lead opportunities
- ADMET property filtering to generate compounds with favorable absorption, distribution, metabolism, excretion, and toxicity profiles
- Custom AI fine-tuning options allowing selection of standard molecular models or bias toward specific structural motifs